drugset / Trial / NCT07588906

To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy Subjects

NCT07588906

Phase 1 Completed 24 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacodynamic profile of a single subcutaneous dose of SHR-3167 injection versus insulin glargine U100 in healthy subjects.

Timeline

Start
2024-02-26
Primary completion
2024-07-12
Completion
2024-07-23

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-3167 Unknown Subcutaneous
Subject insulin glargine Protein / enzyme biologic Subcutaneous

Indications

No indication recorded.